Gamida Cell Revenue and Competitors
Estimated Revenue & Valuation
- Gamida Cell's estimated annual revenue is currently $20.8M per year.
- Gamida Cell's estimated revenue per employee is $155,000
- Gamida Cell's total funding is $267.8M.
- Gamida Cell has 134 Employees.
- Gamida Cell grew their employee count by 10% last year.
Gamida Cell Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Gamida Cell?
Gamida Cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. We are building a broad pipeline based on our proprietary NAM technology platform. Our lead program, NiCord, is in phase 3 development for allogeneic bone marrow transplantation and was granted Breakthrough Therapy Designation by the FDA.keywords:N/A
Number of Employees
Employee Growth %
Gamida Cell News
GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas, Gamida...
Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data from Phase 3 Study of Omidubicel at 2022 Transplantation & Cellular Therapy...
Paul Schloesser. Associate Editor. The small Boston-based cell therapy outfit Gamida Cell recently axed 10% of its workforce in order to...
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today's Virtual R&D Day ● Company recently filed an IND application for GDA-201; FDA placed the application on Clinical Hold pending modifications to donor eligibility procedures and ster ...
Every investor in Gamida Cell Ltd. (NASDAQ:GMDA) should be aware of the most powerful shareholder groups. Insiders often own a large ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|